HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung ...
— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress — — Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS …